Modified-release nicotinamide for the treatment of hyperphosphataemia in haemodialysis patients: 52-week efficacy and safety results of the phase 3 randomized controlled NOPHOS trial.

Markus Ketteler,Andrzej Wiecek,Alexander R Rosenkranz,Claudia Ose,Jan Rekowski,Horst Lorenz,Burkhard Hellmann,Michael Karus,Michaela Ruhmann,Richard Ammer

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association（2023）

引用 4|浏览20

暂无评分

摘要

NAMR combined with phosphate binders significantly reduced serum phosphate over the first 24 weeks of treatment, but the treatment effect was not maintained up to week 52. Non-compliance may have contributed to reduced long-term efficacy. Several newly identified safety signals warrant further evaluation.

查看译文

关键词

haemodialysis,hyperphosphataemia,mineral and bone disease,nicotinamide,randomized controlled trial

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要